Lincoln Pharmaceuticals (NSE:LINCOLN) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lincoln Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lincoln Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Lincoln Pharmaceuticals's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Lincoln Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lincoln Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lincoln Pharmaceuticals LT-Debt-to-Total-Asset Chart

Lincoln Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Lincoln Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Lincoln Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Lincoln Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	0	/	7002.904
	=	0.00

Lincoln Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0	/	0
	=

Lincoln Pharmaceuticals (NSE:LINCOLN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lincoln Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lincoln Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lincoln Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lincoln Pharmaceuticals Ltd (NSE:LINCOLN) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

531633:India

Address

Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060

Website

https://www.lincolnpharma.com

Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.

Lincoln Pharmaceuticals Headlines

No Headlines